Treatment with DYNE-101 is leading to improvements in muscle function — with notable gains in finger function — among people…
Articles by Marisa Wexler, MS
RGX-202, a one-time gene therapy designed to treat Duchenne muscular dystrophy (DMD), has been well tolerated in an ongoing…
The Muscular Dystrophy Association‘s (MDA) annual Clinical & Scientific Conference kicked off over the weekend, bringing together patients,…
The U.S. Food and Drug Administration (FDA) has given Entrada Therapeutics permission to launch a Phase 1b clinical…
Five people with oculopharyngeal muscular dystrophy (OPMD) — a type of muscular dystrophy marked by muscle weakness affecting…
A Phase 1 clinical trial testing SAT-3247, an oral treatment candidate for Duchenne muscular dystrophy (DMD), is now done…
A fundraiser through the online role-playing game World of Warcraft has raised more than $2 million to support CureDuchenne,…
Treatment with oral therapy ifetroban led to improvements in measures of heart function in people with Duchenne muscular dystrophy…
The Muscular Dystrophy Association (MDA) has announced its 2025 Legacy Awards, and will honor two individuals who have made…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DYNE-101, a treatment candidate for myotonic…